Get access
Advanced Materials

Tumor Redox Heterogeneity-Responsive Prodrug Nanocapsules for Cancer Chemotherapy

Authors

  • Jinqiang Wang,

    1. Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    2. Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Xuanrong Sun,

    1. Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Weiwei Mao,

    1. Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Weilin Sun,

    1. Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Jianbin Tang,

    1. Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Meihua Sui,

    1. Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Youqing Shen,

    Corresponding author
    1. Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    • Center for Bionanoengineering and State Key Laboratory of Chemical Engineering, Zhejiang University, Hangzhou 310027, P.R. China
    Search for more papers by this author
  • Zhongwei Gu

    Corresponding author
    1. National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, P.R. China
    • National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, P.R. China.
    Search for more papers by this author

Abstract

A prodrug forms nanocapsules responsive to tumor GSH/ROS heterogeneity releasing the parent drug SN38 via thiolysis in the presence of GSH (glutathione) or via enhanced hydrolysis due to ROS (reactive oxygen species)-oxidation of the linker, giving rise to high in vitro cytotoxicity and in vivo anticancer therapeutic activity. The nanocapsules are a suitable size for tumor targeting by means of the EPR effect and have a fixed SN38 loading content of 35 wt%, ideal for translational nanomedicine.

original image
Get access to the full text of this article

Ancillary